Zimmer Biomet price target lowered to $105 from $120 at Citizens

Citizens lowered the firm’s price target on Zimmer Biomet (ZBH) to $105 from $120 and keeps an Outperform rating on the shares. Zimmer Biomet delivered a modest revenue beat and a stronger EPS outperformance in Q1, largely driven by tariff-related benefits that boosted margins, the analyst tells investors in a research note. While core performance was mixed, the company maintained its revenue outlook and raised its EPS guidance to reflect tariff impacts, with 2026 still viewed as a transitional year, the firm says.